Autonomix Medical Inc. announced the issuance of a new U.S. patent for its minimally invasive nerve-mapping and targeting platform, specifically for treating various cancers and augmenting organ function. This intellectual property covers catheter-based microsurgical tools for recording neural signals and delivering therapeutics, leading to a significant surge in the company's stock price.
Autonomix Medical Inc. (AMIX) has secured U.S. Patent No. 12,433,670, which protects its innovative technology for treating multiple cancers (pancreatic, prostate, breast, colorectal, liver, ovarian, and bone) and augmenting organ function. This patent significantly expands the company's intellectual property portfolio, covering catheter-based microsurgical tools that can map neural activity and modulate the autonomic nervous system. The market has reacted extremely positively, with AMIX shares skyrocketing over 386%, indicating that investors view this as a major de-risking event and a substantial expansion of the company's addressable market. This is a short-term catalyst for AMIX, but also presents a long-term opportunity for the company to develop and commercialize these patented technologies, potentially disrupting cancer treatment paradigms.